Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.

Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A, Bhagat G, Chadburn A, Dalla-Favera R, Pasqualucci L.

Nature. 2009 Jun 4;459(7247):717-21. doi: 10.1038/nature07968. Epub 2009 May 3.

2.

The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology.

Vereecke L, Beyaert R, van Loo G.

Trends Immunol. 2009 Aug;30(8):383-91. doi: 10.1016/j.it.2009.05.007. Epub 2009 Jul 28. Review.

PMID:
19643665
3.

Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?

Barton S, Hawkes EA, Wotherspoon A, Cunningham D.

Oncologist. 2012;17(12):1562-73. doi: 10.1634/theoncologist.2012-0218. Epub 2012 Oct 18. Review.

4.

ABINs: A20 binding inhibitors of NF-kappa B and apoptosis signaling.

Verstrepen L, Carpentier I, Verhelst K, Beyaert R.

Biochem Pharmacol. 2009 Jul 15;78(2):105-14. doi: 10.1016/j.bcp.2009.02.009. Epub 2009 Feb 27. Review.

PMID:
19464428
5.

Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.

Knittel G, Liedgens P, Korovkina D, Pallasch CP, Reinhardt HC.

Eur J Haematol. 2016 Dec;97(6):499-510. doi: 10.1111/ejh.12792. Epub 2016 Sep 8. Review.

PMID:
27526684
6.

Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma.

Dobashi A.

J Clin Exp Hematop. 2016;56(2):71-78. Review.

7.

Oncogenic activation of NF-kappaB.

Staudt LM.

Cold Spring Harb Perspect Biol. 2010 Jun;2(6):a000109. doi: 10.1101/cshperspect.a000109. Epub 2010 Apr 21. Review.

8.

B-cell receptor signaling in diffuse large B-cell lymphoma.

Young RM, Shaffer AL 3rd, Phelan JD, Staudt LM.

Semin Hematol. 2015 Apr;52(2):77-85. doi: 10.1053/j.seminhematol.2015.01.008. Epub 2015 Jan 15. Review.

9.

Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-kappaB pathway as a target for new therapeutic strategies.

Pavan A, Spina M, Canzonieri V, Sansonno S, Toffoli G, De Re V.

Leuk Lymphoma. 2008 Nov;49(11):2048-58. doi: 10.1080/10428190802444176. Review.

PMID:
19021048
10.

A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme.

Malynn BA, Ma A.

J Exp Med. 2009 May 11;206(5):977-80. doi: 10.1084/jem.20090765. Epub 2009 Apr 20. Review.

11.

[Frequent inactivation of A20 through gene mutation in B-cell lymphomas].

Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K, Niwa A, Chen Y, Nakazaki K, Nomoto J, Asakura Y, Akatsuka M, Hayashi Y, Mori H, Igarashi T, Kurokawa M, Chiba S, Mori S, Ishikawa Y, Okamoto K, Tobinai K, Nakagama H, Nakahata T, Yoshino T, Kobayashi Y, Ogawa S.

Rinsho Ketsueki. 2011 Jun;52(6):313-9. Review. No abstract available.

PMID:
21737982
12.

[Significance of A20 in B-cell lymphomas].

Kato M, Ogawa S.

Rinsho Ketsueki. 2011 Apr;52(4):190-7. Review. Japanese. No abstract available.

PMID:
21566404
13.

TP53 dysfunction in diffuse large B-cell lymphoma.

Lu TX, Young KH, Xu W, Li JY.

Crit Rev Oncol Hematol. 2016 Jan;97:47-55. doi: 10.1016/j.critrevonc.2015.08.006. Epub 2015 Aug 10. Review.

PMID:
26315382
14.
15.

B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease.

Koff JL, Flowers CR.

Expert Rev Hematol. 2016 Jun;9(6):553-61. doi: 10.1080/17474086.2016.1180972. Epub 2016 May 13. Review.

PMID:
27098121

Supplemental Content

Support Center